Name Development Level Target Family
Name Description
brentuximab vedotin a CD30-directed antibody-drug conjugate consisting of three components: the chimeric IgG1 antibody cAC10, specific for human CD30, the microtubule disrupting agent MMAE, and a protease-cleavable linker that covalently attaches MMAE to cAC10
TCRDv4.6.9
DrugCentral Indication
DrugCentral
brentuximab vedotin